Abstract: The present invention is a composition comprising (a) a coating base selected from a water-dispersed coating, an epoxy polymer coating, an alkyd coating, a Type I urethane coating, or an unsaturated polyester coating; and (b) a fluorinated ester compound represented by Formula (I): [AsY(CH2)x-Q-Z—(CH2)y—Rf]t??(I) where A is independently —OH, a C1-C18 alkyl, —CH2OH, —CH2COOH, or (CH2CH2O)a(CH2CH(CH3)O)bH; a and b are independently 0 to 3, where a+b is 1 to 3; s is 0 to 2; Y is a linear or branched alkylene organic group having t+s substitutions; x is 0 or 1; Q is —C(O)O— or —OC(O)—; Z is —(CH2)yS— or —(CH2CH2O)m(CH2CH(CH3)O)n—; y is 2 to 6; m and n are independently 0 to 6, where m+n is 1 to 6; Rf is a straight or branched perfluoroalkyl group of 2 to 20 carbon atoms; and t is 2 to 6, such that s+t is 2 to 6.

Abstract: A synthesis method of 3,4-hexanedione comprises a step of 4-hydroxy-3-hexanonen oxidation, and in the step of 4-hydroxy-3-hexanonen oxidation, water is used as a catalyst, acetic acid is used as a cocatalyst, and ozone is used as an oxidizing agent to carry out an oxidation reaction on 4-hydroxy-3-hexanonen, and after the reaction, distillation under reduced pressure is carried out to obtain the 3,4-hexanedione. According to the synthesis method of 3,4-hexanedione in the invention, in the process of 4-hydroxy-3-hexanone oxidation, the 4-hydroxy-3-hexanone is placed in the water, the ozone is used for oxidation on the 4-hydroxy-3-hexanone, and the acetic acid is used as the cocatalyst, so that the entire oxidation reaction process is mild in conditions and simple to operate, no sewage is produced when the final product (3,4-hexanedione) is obtained, and the yield is greatly increased.

Abstract: This disclosure relates to new metal complexes, such as compounds of Formula 1, and their application in olefin or alkyne metathesis and to methods of carrying out olefin metathesis reactions.

Abstract: The present invention relates to the cinchonidine salt useful in the preparation of intermediates for preparing a macrocyclic HCV inhibitor, as well as processes involving this salt.

Abstract: One embodiment of the invention provides polyisobutylene (PIB) oligormers that are end-functionalized with ruthenium (Ru) catalysts. Such nonpolar catalysts can be dissolved in nonpolar solvents such as heptane, or any other nonpolar solvent that is otherwise not latently biphasic (i.e., if two or more solvent components are present, they remain miscible with each other throughout the entire reaction process, from the addition of substrate through to the removal of product). Substrate that is dissolved in the nonpolar solvent with the catalyst is converted into product. The lower solubility of the product in the nonpolar solvent renders it easily removable, either by extraction with a more polar solvent or by applying physical means in cases where the product precipitates from the nonpolar solvent. In this manner the catalysts are recycled; since the catalysts remain in the nonpolar solvent, a new reaction can be initiated simply by dissolving fresh substrate into the nonpolar solvent.

Abstract: The invention is directed to ruthenium-based metathesis catalysts of the Hoveyda-Grubbs type. The new N-chelating diarylamino-based ruthenium catalysts described herein are stable in solid state and in solution and reveal rapid initiation behavior. Further, the corresponding N-substituted styrene precursor compounds are disclosed. The catalysts are prepared in a cross-metathesis reaction starting from N-substituted styrene precursors. The new Hoveyda-Grubbs type catalysts are suitable to catalyze ring-closing metathesis (RCM), cross metathesis (CM) and ring-opening metathesis polymerization (ROMP). Low catalyst loadings are sufficient to convert a wide range of substrates via metathesis reactions.

Abstract: The invention relates to the method of preparation of compounds of formula I, the precursors of homocitric acid lactone and its salts, by coupling of the compounds of formula II with bromoacetic acid esters of formula III.

Abstract: This invention relates to geranylgeranyl acetone (GGA) derivatives and the use of GGA, its isomers, and GGA derivatives in methods for inhibiting neural death, increasing neural activity, increasing axon growth and cell viability, and increasing the survival rate of subjects administered the GGA or GGA derivatives.

Abstract: The present invention relates to the cinchonidine salt useful in the preparation of intermediates for preparing a macrocyclic HCV inhibitor, as well as processes involving this salt.

Abstract: The present invention relates to a cationic lipid of formula (I) having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

Abstract: The invention relates to the method of preparation of compounds of formula I, the precursors of homocitric acid lactone and its salts, by coupling of the compounds of formula II with bromoacetic acid esters of formula III.

Abstract: Provided herein are ruthenium complexes of Formula I, and processes of preparation thereof. Also provided are methods of their use as a metathesis catalyst.

Abstract: The present invention relates to cosmetic and/or personal care formulations and/or compounds. In one embodiment, the present invention relates to ester compounds that can be used in various personal care formulations and/or compounds. In another embodiment, the present invention relates to branced ester compounds having a molecular weight of at least about 1,500 daltons that can be used in various personal care formulations and/or compounds.

Abstract: The present application provides, among other things, novel compounds and methods for metathesis reactions. In some embodiments, a provided compound has the structure of formula I. In some embodiments, the present invention provides methods for preparing a compound of formula I. In some embodiments, the present invention provides metathesis methods comprising providing a compound of formula I.

Abstract: The invention provides novel organometallic complexes useful as olefin metathesis catalysts. The complexes have an N-heterocyclic carbene ligand and a chelating carbene ligand associated with a Group 8 transition metal center. The molecular structure of the complexes can be altered so as to provide a substantial latency period. The complexes are particularly useful in catalyzing ring closing metathesis of acyclic olefins and ring opening metathesis polymerization of cyclic olefins.

Abstract: The invention relates to metal complexes of general formula (I) and to a method for the production thereof, in which M, R1, R2, R3, X and Y in addition to Ra, Rb, Rc, Rd, Re, Rf, Rg, Rh can have the meanings defined in the claims. Said metal complexes form air-stable compounds and are suitable as pre-catalysts in the olefin metathesis.

Abstract: The present invention relates to catalytically active compounds of the general formula (1) that are highly tunable, as well as to a method of their preparation and their use in any type metathesis reaction. The new compounds of the present invention comprise activation sites that allow for specific catalyst design. Particularly, side chains and ligands allow efficient activity and specificity control of the catalysts of the present invention.

Abstract: New low molecular weight complexes between iron and maltobionic acid that can be administered parenterally, preferably intramuscularly or subcutaneously, in the treatment of anemic states, caused by iron deficiencies, and new pharmaceutical compositions adapted for this use. In particular, the invention provides a new complex between preferably trivalent iron and maltobionic acid that is characterized by a molecular weight Mw between 10,000 and 30,000 Da, by a polydispersity of 1.0-1.8 and by an iron content between 25% and 40% by weight.

Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as “APSAC compounds”).

Abstract: Cis and trans ruthenium complexes that can be used as catalysts for ring opening metathesis polymerisation (ROMP) are described. The complexes are generally square pyramidal in nature, having two anionic ligands X. Corresponding cationic complexes where one or both of the anionic ligands X are replaced by a non-co-ordinating anionic ligand are also described. Polymers such as polydicyclopentadiene (PDCPD) can be prepared using the catalysts.

Abstract: Disclosed is a process for the preparation of a cinchonidine salt of formula (IV) via an aqueous solution of a racemic 4-hydroxy-1,2-cyclopentanedicarboxylic acid, which is subjected to cyclization without removing water, by the addition of a water-miscible organic solvent to the aqueous solution and, again without removing water, adding cinchonidine to the aqueous-organic solvent solution so as to obtain the cinchonidine salt of the lactone acid. The cinchonidine salt is allowd to crystallize so as to obtain the enantiomerically purified crystalline lactone acid cinchonidine salt (IV). The enantiomerically pure salt is an intermediate in the synthesis of HCV inhibitor compound of formula (I).

Abstract: The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo.

Abstract: Disclosed are neuraminidase inhibitor compounds and pharmaceutical compositions with improved bioavailability and/or improved efficacy and methods of treating influenza using the compounds and pharmaceuticals compositions.

Abstract: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.

Abstract: The present invention provides new ruthenium complexes of Formula (1), which contain a chelate ring created by a halogen atom X. The invention concerns also a method for the preparation of the new ruthenium complexes and their application in metathesis reactions.

Abstract: Sulfur chelated ruthenium compounds represented by the following formula: wherein M indicates the ruthenium metal bound to a benzylidene carbon; R represents C1-C7 alkyl group or optionally substituted aryl; X1 and X2 each independently represent halogen; Y1 and Y2 each independently denote unsubstituted or alkyl-substituted phenyl; and Z independently represents hydrogen, electron withdrawing or electron donating substituent, with m being an integer from 1 to 4, and processes and compositions related thereto.

Abstract: A cage 1,2,3,4-cyclopentanetetracarboxylic acid (1,3:2,4)-dianhydride compound represented by formula [1], and a polyimide obtained by condensing the compound with a diamine. With the compound, it is possible to provide a polyimide which shows no absorption in the ultraviolet region and is highly transparent to light, has high insulating properties, has improved heat resistance and processability, and has excellent solubility in organic solvents. (In formula [1], R1 and R2 each independently represents a hydrogen atom, a halogen atom, or a C1-10 alkyl.

Abstract: This disclosure relates to new metal complexes, such as compounds of Formula 1, and their application in olefin or alkyne metathesis and to methods of carrying out olefin metathesis reactions.

Abstract: The invention is directed to aryl alkylidene ruthenium complexes and the use of these complexes as catalysts in metathesis reactions.

Abstract: The invention relates to compounds of general formula I, (I), wherein R is wherein R is aryl substituted by R3; or R is (C3-Ci3)-cycloalkyl, (C3-Ci3)-cycloalkenyl or (C7-Ci3)-cycloalkynyl optionally substituted by R4; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.

Abstract: The invention provides novel organometallic complexes useful as olefin metathesis catalysts. The complexes have an N-heterocyclic carbene ligand and a chelating carbene ligand associated with a Group 8 transition metal center. The molecular structure of the complexes can be altered so as to provide a substantial latency period. The complexes are particularly useful in catalyzing ring closing metathesis of acyclic olefins and ring opening metathesis polymerization of cyclic olefins.

Abstract: This invention relates to geranylgeranyl acetone (GGA) derivatives and the use of GGA, its isomers, and GGA derivatives in methods for inhibiting neural death, increasing neural activity, increasing axon growth and cell viability, and increasing the survival rate of subjects administered the GGA or GGA derivatives.

Abstract: A radiation-sensitive resin composition includes a compound represented by a formula (1), and a polymer that includes a structural unit having an acid-labile group. R1 and R4 each independently represent a hydrogen atom, or the like. R2 and R3 each independently represent a hydrogen atom or the like. X1 and X2 each independently represent a hydrogen atom, or the like, or X1 and X2 taken together represent —S—, —O—, —SO2—, or the like. A represents an ethanediyl group, wherein at least one hydrogen atom included in X1, X2 and A is substituted by —Y—SO3?M+. Y represents an alkanediyl group having 1 to 10 carbon atoms, or the like. M+ represents a monovalent onium cation. In the case where —Y—SO3?M+ is present in a plurality of number, a plurality of Ys are each identical or different and a plurality of M+s are each identical or different.

Abstract: Provided herein are ruthenium complexes of Formula I, and processes of preparation thereof. Also provided are methods of their use as a metathesis catalyst.

Abstract: Catalytic complexes including a metal atom having anionic ligands, at least one nucleophilic carbene ligand, and an alkylidene, vinylidene, or allenylidene ligand. The complexes are highly stable to air, moisture and thermal degradation. The complexes are designed to efficiently carry out a variety of olefin metathesis reactions.

Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as “APSAC compounds”).

Abstract: There is disclosed compounds of formula 1, their preparation, intermediates for the preparation and the use of the compounds of the formula 1 as catalysts in various metathesis reactions. The novel metathesis catalysts, which are obtained from readily available precursors, have a high activity and can be used for any type of metathesis reaction.

Abstract: The present invention relates to catalytically active compounds of the general formula (1) that are highly tunable, as well as to a method of their preparation and their use in any type metathesis reaction. The new compounds of the present invention comprise activation sites that allow for specific catalyst design. Particularly, side chains and ligands allow efficient activity and specificity control of the catalysts of the present invention.

Abstract: Cls ruthenium complexes that can be used as catalysts are described. The complexes are generally square pyramidal in nature, having two anionic ligands X adjacent to each other. The complexes can be used as catalysts, for example in olefin metathesis reactions. Corresponding trans ruthenium complexes are also described, together with cationic complexes where one or both of the anionic ligands X are replaced by a non-co-ordinating anionic ligand.

Abstract: Provided herein are ruthenium complexes of Formula I, and processes of preparation thereof. Also provided are methods of their use as a metathesis catalyst.

Abstract: Provided herein are geranylgeranylacetone derivatives and methods of using them.

Abstract: The present invention relates to [1] a process for producing a 2-alkyl-2-cycloalken-1-one represented by the following general formula (2), which includes the step of subjecting a 2-(1-hydroxyalkyl)cycloalkan-1-one to dehydration and isomerization in the co-existence of an acid and a platinum group metal catalyst, and [2] a process for producing an alkyl(3-oxo-alkylcycloalkyl)acetate which is useful as a perfume material, using the 2-alkyl-2-cycloalken-1-one: wherein n is an integer of 1 or 2; and R1 and R2 are each independently a hydrogen atom or an alkyl group having 1 to 8 carbon atoms with the proviso that R1 and R2 may form a ring through a carbon atom adjacent thereto.

Abstract: This invention relates to methods of making a compound of formula (I) and intermediates for same the compounds of formula (I) being useful for treating cardiovascular and inflammatory diseases such as atherosclerosis.

Abstract: Gold (I) hydroxide complexes of the form Z-Au-OH and digold complexes of the form Z—Au-(?OH)—Au—Z where groups Z are two electron donors are provided. The groups Z may be carbenes, for example nitrogen containing heterocyclic carbenes (NHCs), phosphines or phosphites. The complexes can be used as catalysts, for example in reactions such as hydration of nitriles, skeletal arrangement of enynes, alkoxycyclisation of enynes, alkyne hydration, the Meyer-Shuster reaction, 3,3? rearrangement of allylic acetates, cyclisation of propargylic acetates, Beckman rearrangements and hydroamination. The complexes can be used in medicine, for example in the treatment of cancer.

Abstract: Disclosed are neuraminidase inhibitor compounds and pharmaceutical compositions with improved bioavailability and/or improved efficacy and methods of treating influenza using the compounds and pharmaceuticals compositions.

Abstract: A compound represented by general formula (a-i) below, and a polymeric compound having a structural unit represented by general formula (a-ii) below (wherein R represents a hydrogen atom, a lower alkyl group or a halogenated lower alkyl group; X represents a divalent organic group represented by general formula (x-1) below; and R1 represents an organic group having a fluorine atom).

Abstract: The method for making a phosphorus ylide produces the ylide 2,3-bismethoxycarbonyl-4-phenyl-5-arylhydrazono-cyclopenta-1,3-dienyl-triphenylphosphonium in pure form by simple recrystallization of the reaction product. 3-Oxo-3-phenyl-2-(arylhydrozono)propanal and dimethylacetylenedicarboxylate are mixed in dichloromethane at room temperature. After cyclization of the intermediate (preferably at least two hours), triphenylphosphine is added to the mixture, ultimately resulting in formation of 2,3-bismethoxycarbonyl-4-phenyl-5-arylhydrazono-cyclopenta-1,3-dienyl-triphenylphosphonium. The product is recrystallized to produce 2,3-bismethoxycarbonyl-4-phenyl-5-arylhydrazono-cyclopenta-1,3-dienyl-triphenylphosphonium in pure form and in high yield. The aryl group may be any aromatic or aliphatic group.

Abstract: Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof are disclosed, wherein a dashed line represents the presence or absence of a bond; and, wherein Y, A, R, D, and n are as described. Methods, compositions, and medicaments related thereto are also disclosed.

Abstract: Provided are compounds, compositions, and methods for treating diseases and conditions wherein an inhibitor of a kinase, such as rho kinase (ROCK), and an inhibitor of one or more of the monoamine transporters, such as NET or SERT, act in concert to improve the condition.

Abstract: The invention provides seed treatment compositions as well as their use, methods for treating seeds, methods of protecting plants against pests and also treated seeds and plants. In one embodiment there is provided a method of treating a seed with a seed treatment composition to induce a plant resistance mechanism against one or more pests in a plant grown from said seed.